HomeREGISTERREGISTERSITEMAPContact us
Home > Available Issues
Original Articles
Efficacy of the Arbekacin and Teicoplanin Combination on Glycopeptide Intermediate Staphylococcus aureus in a Rabbit Model of Endocarditis
Cheong Ho Cho1, Jun Yong Choi1, Sang Hoon Han1, Han Sung Lee1, Suk Hoon Choi1, Bum Sik Chin1, Hee Kyoung Choi1, Su Jin Jeoung1, Myung Soo Kim1, Chang Oh Kim1, Chang Ki Kim2, Dongeun Yong2, Young Goo Song1, Kyungwon Lee2 and June Myung Kim1
1Department of Internal Medicine and AIDS Research Institute, 2Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
Vol.40 Num.2 (p102~106)
Background:There have been no reports to evaluate the usefulness of combination therapy with glycopeptide and arbekacin in endocarditis by in vivo model.
Materials and Methods:We investigated the efficacy of the arbekacin and teicoplanin combination on glycopeptide intermediate Staphylococcus aureus (GISA) in rabbit model of endocardits. GISA Mu50 strain was used for the experiment. The rabbit model of aortic valve endocarditis as described previously was used. Treatment was started 20h later inoculation with teicoplanin alone (at 20 mg/kg of body weight intramuscularly every 12 hours for 4 days after loading dose of 40 mg/kg of body weight intramuscularly), arbekacin alone (5 mg/kg of body weight intramuscularly every 12h for 4 days), or teicoplanin plus arbekacin.
Results:The results of therapy for experimental endocarditis due to Mu50 showed that teicoplanin and arbekacin combination was more effective than the administration of both drugs alone in reducing the log10CFU/g of aortic vegetation (P?0.05).
Conclusion:The combination of teicoplanin and arbekacin was more effective against GISA (Mu50) than both drugs alone in vivo endocarditis model.
Keywords : Endocarditis, Staphylococcus aureus, Teicoplanin, Arbekacin